Cargando…
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Several clinical trials started during the COVID-19 pandemic to discover effective therapeutics led to identify a few candidates from the major clinical trials. However, in the past several months, quite a few SARS-CoV-2 variants have emerged with significant mutations. Major mutations in the S-glyc...
Autores principales: | Chakraborty, Chiranjib, Bhattacharya, Manojit, Sharma, Ashish Ranjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606259/ https://www.ncbi.nlm.nih.gov/pubmed/34920267 http://dx.doi.org/10.1016/j.coph.2021.11.006 |
Ejemplares similares
-
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations
por: Chakraborty, Chiranjib, et al.
Publicado: (2022) -
Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape
por: Bhattacharya, Manojit, et al.
Publicado: (2022) -
Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
por: Bhattacharya, Manojit, et al.
Publicado: (2022) -
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants
por: Chakraborty, Chiranjib, et al.
Publicado: (2021) -
Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)